Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 4 (April)

1. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients.
   J Electrocardiol, 39(2): 199-205. [Abstract] [Full-text]
2. High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups.
   Infect Genet Evol, 6(3): 198-204. [Abstract] [Full-text]
3. Selective transmission of hepatitis C virus quasi species through a needlestick accident in acute resolving hepatitis.
   Clin Infect Dis, 42(9): 1254-9. [Abstract] [Full-text]
4. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers.
   J Infect Dis, 193(9): 1258-65. [Abstract] [Full-text]
5. HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability.
   J Infect Dis, 193(9): 1211-8. [Abstract] [Full-text]
6. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana.
   J Med Microbiol, 55: 593-7. [Abstract] [Full-text]
7. Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection.
   Liver Int, 26(3): 326-33. [Abstract] [Full-text]
8. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
   Liver Int, 26(3): 319-25. [Abstract] [Full-text]
9. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C.
   Liver Int, 26(3): 311-8. [Abstract] [Full-text]
10. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis.
    Liver Int, 26(3): 305-10. [Abstract] [Full-text]
11. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis.
    Liver Int, 26(3): 298-304. [Abstract] [Full-text]
12. Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis C.
    Liver Int, 26(3): 279-84. [Abstract] [Full-text]
13. Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis.
    J Clin Invest, 116(4): 1045-51. [Abstract] [Full-text]
14. On DNA vaccines and prolonged expression of immunogens.
    Eur J Immunol, 36(4): 806-9. [Abstract] [Full-text]
15. Long-term persistence of hepatitis B surface antigen and antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice.
    Eur J Immunol, 36(4): 875-86. [Abstract] [Full-text]
16. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.
    Ann Pharmacother, 40(4): 753-7. [Abstract] [Full-text]
17. Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman.
    J Clin Microbiol, 44(4): 1584-6. [Abstract] [Full-text]
18. Evaluation of diagnostic assays for hepatitis E virus in outbreak settings.
    J Clin Microbiol, 44(4): 1581-3. [Abstract] [Full-text]
19. Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high-risk individuals.
    J Clin Microbiol, 44(4): 1561-3. [Abstract] [Full-text]
20. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.
    J Clin Microbiol, 44(4): 1390-9. [Abstract] [Full-text]
21. Molecular epidemiology and evolution in an outbreak of fulminant hepatitis B virus.
    J Clin Microbiol, 44(4): 1288-94. [Abstract] [Full-text]
22. L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury.
    J Leukoc Biol, 79(4): 696-705. [Abstract] [Full-text]
23. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness.
    Psychiatr Serv, 57(4): 570-2. [Abstract] [Full-text]
24. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus.
    Am J Physiol Gastrointest Liver Physiol, 290(5): G847-51. [Abstract] [Full-text]
25. Analysis of the entire nucleotide sequence of hepatitis B virus genotype B in the Philippines reveals a new subgenotype of genotype B.
    J Gen Virol, 87: 1175-80. [Abstract] [Full-text]
26. Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations.
    J Gen Virol, 87: 1163-73. [Abstract] [Full-text]
27. Management of chronic hepatitis B and C in HIV-coinfected patients.
    J Antimicrob Chemother, 57(5): 815-8. [Abstract] [Full-text]
28. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.
    Proc Natl Acad Sci U S A, 103(15): 6001-6. [Abstract] [Full-text]
29. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection.
    Gut, 55(5): 715-8. [Abstract] [Full-text]
30. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors.
    Braz J Med Biol Res, 39(4): 525-31. [Abstract] [Full-text]
31. HCV and HIV infection and co-infection: injecting drug use and sexual behavior, AjUDE-Brasil I Project.
    Cad Saude Publica, 22(4): 839-48. [Abstract] [Full-text]
32. The contribution of two Brazilian multi-center studies to the assessment of HIV and HCV infection and prevention strategies among injecting drug users: the AjUDE-Brasil I and II Projects.
    Cad Saude Publica, 22(4): 771-82. [Abstract] [Full-text]
33. Investigating the origin and spread of hepatitis C virus genotype 5a.
    J Virol, 80(9): 4220-6. [Abstract] [Full-text]
34. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor.
    Am J Transplant, 6(5): 1077-83. [Abstract] [Full-text]
35. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
    Aliment Pharmacol Ther, 23(8): 1171-8. [Abstract] [Full-text]
36. Assessing patients' understanding of hepatitis C virus infection and its impact on their lifestyle.
    Aliment Pharmacol Ther, 23(8): 1161-70. [Abstract] [Full-text]
37. Effect of anti-viral therapy for occult hepatitis C virus infection.
    Aliment Pharmacol Ther, 23(8): 1153-9. [Abstract] [Full-text]
38. Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population.
    Aliment Pharmacol Ther, 23(8): 1105-12. [Abstract] [Full-text]
39. Review article: predicting response in hepatitis C virus therapy.
    Aliment Pharmacol Ther, 23(8): 1043-54. [Abstract] [Full-text]
40. Review article: hepatitis B and liver transplantation.
    Aliment Pharmacol Ther, 23(8): 1031-41. [Abstract] [Full-text]
41. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.
    J Viral Hepat, 13(4): 278-88. [Abstract] [Full-text]
42. Is hepatitis C virus a risk factor for thyroid autoimmunity?
    J Viral Hepat, 13(4): 272-7. [Abstract] [Full-text]
43. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.
    J Viral Hepat, 13(4): 264-71. [Abstract] [Full-text]
44. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
    J Viral Hepat, 13(4): 256-63. [Abstract] [Full-text]
45. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
    J Viral Hepat, 13(4): 250-5. [Abstract] [Full-text]
46. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.
    J Viral Hepat, 13(4): 242-9. [Abstract] [Full-text]
47. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
    J Viral Hepat, 13(4): 235-41. [Abstract] [Full-text]
48. Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin.
    J Viral Hepat, 13(4): 230-4. [Abstract] [Full-text]
49. A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a.
    J Viral Hepat, 13(4): 222-9. [Abstract] [Full-text]
50. Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease.
    J Viral Hepat, 13(4): 217-21. [Abstract] [Full-text]
51. Assisted procreation in cases of hepatitis B, hepatitis C or human immunodeficiency virus infection of the male partner.
    Hum Reprod, 21(5): 1117-21. [Abstract] [Full-text]
52. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP.
    Dig Dis Sci, 51(4): 808-12. [Abstract] [Full-text]
53. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy.
    Cancer Epidemiol Biomarkers Prev, 15(4): 683-9. [Abstract] [Full-text]
54. Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population.
    J Neurol Neurosurg Psychiatry, 77(5): 626-9. [Abstract] [Full-text]
55. Provider-patient in-office discussions of response to hepatitis C antiviral therapy and impact on patient comprehension.
    Clin Gastroenterol Hepatol, 4(4): 507-13. [Abstract] [Full-text]
56. Y chromosome loss and other genomic alterations in hepatocellular carcinoma cell lines analyzed by CGH and CGH array.
    Cancer Genet Cytogenet, 166(1): 56-64. [Abstract] [Full-text]
57. The role of Epstein-Barr virus in acute and chronic hepatitis.
    J Hepatol, 44(5): 879-85. [Abstract] [Full-text]
58. Association between vitamin D receptor, CCR5, TNF-alpha and TNF-beta gene polymorphisms and HBV infection and severity of liver disease.
    J Hepatol, 44(5): 856-63. [Abstract] [Full-text]
59. Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells.
    J Hepatol, 44(5): 869-78. [Abstract] [Full-text]
60. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis.
    J Hepatol, 44(5): 848-55. [Abstract] [Full-text]
61. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis.
    J Hepatol, 44(5): 864-8. [Abstract] [Full-text]
62. Entecavir: a new treatment option for chronic hepatitis B.
    J Clin Virol, 36(1): 8-12. [Abstract] [Full-text]
63. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection.
    J Clin Virol, 36(1): 24-31. [Abstract] [Full-text]
64. Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes.
    J Hepatol, 44(5): 842-7. [Abstract] [Full-text]
65. Assessment of peripheral DNA damage by alkaline comet assay in maintenance hemodialysis subjects with hepatitis C infection.
    Mutat Res, 596(1): 137-42. [Abstract] [Full-text]
66. Commercial enzyme immunoassay adapted for the detection of antibodies to hepatitis C virus in dried blood spots.
    J Clin Virol, 36(1): 68-71. [Abstract] [Full-text]
67. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
    J Clin Virol, 36(1): 60-3. [Abstract] [Full-text]
68. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 46(7): 762-6. [Abstract] [Full-text]
69. Trait positive affect and antibody response to hepatitis B vaccination.
    Brain Behav Immun, 20(3): 261-9. [Abstract] [Full-text]
70. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus.
    J Infect Dis, 193(10): 1371-4. [Abstract] [Full-text]
71. A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for hepatitis C.
    J Infect Dis, 193(10): 1365-70. [Abstract] [Full-text]
72. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study.
    Clin Infect Dis, 42(10): 1481-7. [Abstract] [Full-text]
73. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
    Gastroenterology, 130(4): 1144-52. [Abstract] [Full-text]
74. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor.
    Gastroenterology, 130(4): 1129-34. [Abstract] [Full-text]
75. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism.
    Gastroenterology, 130(4): 1107-16. [Abstract] [Full-text]
76. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Gastroenterology, 130(4): 1098-106. [Abstract] [Full-text]
77. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
    Gastroenterology, 130(4): 1086-97. [Abstract] [Full-text]
78. Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus.
    Electrophoresis, 27(8): 1651-8. [Abstract] [Full-text]
79. Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine.
    J Pharmacol Exp Ther, 317(2): 635-43. [Abstract] [Full-text]
80. Protective effect of paeoniflorin on immunological liver injury induced by bacillus Calmette-Guerin plus lipopolysaccharide: modulation of tumour necrosis factor-alpha and interleukin-6 MRNA.
    Clin Exp Pharmacol Physiol, 33(4): 332-9. [Abstract] [Full-text]
81. Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection.
    Clin Exp Pharmacol Physiol, 33(4): 300-4. [Abstract] [Full-text]
82. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
83. Significance of alterations in PBMC immunophenotype of children with chronic viral hepatitis C-- the role of dendritic cells.
    Scand J Immunol, 63(4): 311-9. [Abstract] [Full-text]
84. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country.
    Transfus Med, 16(2): 79-83. [Abstract] [Full-text]
85. Oval cells in hepatitis B virus-positive and hepatitis C virus-positive liver cirrhosis: histological and ultrastructural study.
    Histopathology, 48(5): 546-55. [Abstract] [Full-text]
86. Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    AIDS Res Hum Retroviruses, 22(4): 315-20. [Abstract] [Full-text]
87. Alternative peptide-fusion proteins generated by out-of-frame mutations, just upstream ORFs or elongations in mutants of human hepatitis B viruses.
    Virus Res, 117(2): 185-201. [Abstract] [Full-text]
88. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.
    Oncogene, 25(17): 2537-45. [Abstract] [Full-text]
89. Nosocomial transmission of hepatitis C virus from an anesthesiologist to three patients--epidemiologic and molecular evidence.
    Arch Virol, 151(5): 1025-30. [Abstract] [Full-text]
90. "The first shot": the context of first injection of illicit drugs, ongoing injecting practices, and hepatitis C infection in Rio de Janeiro, Brazil.
    Cad Saude Publica, 22(4): 861-70. [Abstract] [Full-text]
91. Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender.
    J Clin Gastroenterol, 40(4): 358-66. [Abstract] [Full-text]
92. Rebiopsy in patients with untreated hepatitis C: a useful procedure.
    J Clin Gastroenterol, 40(4): 347-52. [Abstract] [Full-text]
93. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches.
    J Clin Gastroenterol, 40(4): 322-35. [Abstract] [Full-text]
94. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study.
    Eur Psychiatry, 21(3): 204-10. [Abstract] [Full-text]
95. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection.
    J Pain Symptom Manage, 31(4): 335-44. [Abstract] [Full-text]
96. Infectious disease in the blood supply and the public health response.
    Semin Hematol, 43(2): S4-9. [Abstract] [Full-text]
97. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
    Ann Thorac Surg, 81(5): 1851-2. [Abstract] [Full-text]
98. Evaluating the evidence from clinical trials in chronic hepatitis C.
    J Viral Hepat, 13: 15-25. [Abstract] [Full-text]
99. Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C.
    J Viral Hepat, 13: 6-14. [Abstract] [Full-text]
100. Assessing evidence from clinical trials in chronic hepatitis C.
     J Viral Hepat, 13: 1-5. [Abstract] [Full-text]
101. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
     HIV Med, 7(4): 248-54. [Abstract] [Full-text]
102. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases.
     Aliment Pharmacol Ther, 23(9): 1347-53. [Abstract] [Full-text]
103. Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease.
     Liver Int, 26(4): 439-44. [Abstract] [Full-text]
104. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
     Liver Int, 26(4): 399-405. [Abstract] [Full-text]
105. Definition and management of anemia in patients infected with hepatitis C virus.
     Liver Int, 26(4): 389-98. [Abstract] [Full-text]
106. Gastrointestinal endoscopy decontamination failure and the risk of transmission of blood-borne viruses: a review.
     J Hosp Infect, 63(1): 1-13. [Abstract] [Full-text]
107. Retrospective investigation of patients exposed to possible transmission of hepatitis C virus by a capillary blood glucose meter.
     J Hosp Infect, 63(1): 65-9. [Abstract] [Full-text]
108. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan.
     Int J Cancer, 119(1): 192-5. [Abstract] [Full-text]
109. Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein.
     Virology, 347(2): 466-75. [Abstract] [Full-text]
110. EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs.
     Virus Res, 118(1): 150-5. [Abstract] [Full-text]
111. Epidermolysis bullosa acquisita occurring in 2 patients with hepatitis C.
     J Am Acad Dermatol, 54(5): 888-91. [Abstract] [Full-text]
112. Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels.
     Clin Exp Immunol, 144(2): 188-96. [Abstract] [Full-text]
113. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials.
     Am J Gastroenterol, 101(4): 842-7. [Abstract] [Full-text]
114. Racial difference in mortality among U.S. veterans with HCV/HIV coinfection.
     Am J Gastroenterol, 101(4): 760-7. [Abstract] [Full-text]
115. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis.
     Am J Gastroenterol, 101(4): 831-8. [Abstract] [Full-text]
116. Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation.
     Scand J Gastroenterol, 41(5): 592-6. [Abstract] [Full-text]
117. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C.
     Scand J Gastroenterol, 41(5): 577-85. [Abstract] [Full-text]
118. Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases.
     J Viral Hepat, 13(5): 351-4. [Abstract] [Full-text]
119. Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection.
     J Viral Hepat, 13(5): 343-50. [Abstract] [Full-text]
120. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients.
     J Viral Hepat, 13(5): 336-42. [Abstract] [Full-text]
121. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status.
     J Viral Hepat, 13(5): 329-35. [Abstract] [Full-text]
122. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection.
     J Viral Hepat, 13(5): 322-8. [Abstract] [Full-text]
123. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.
     J Viral Hepat, 13(5): 316-21. [Abstract] [Full-text]
124. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.
     J Viral Hepat, 13(5): 311-5. [Abstract] [Full-text]
125. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis.
     J Viral Hepat, 13(5): 303-10. [Abstract] [Full-text]
126. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years.
     J Viral Hepat, 13(5): 290-6. [Abstract] [Full-text]
127. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
     Liver Transpl, 12(5): 827-30. [Abstract] [Full-text]
128. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation.
     Liver Transpl, 12(5): 801-7. [Abstract] [Full-text]
129. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis.
     Liver Transpl, 12(5): 736-46. [Abstract] [Full-text]
130. Hepatitis B virus genotypes, core promoter variants, and precore stop codon variants in patients infected chronically in North-Eastern Italy.
     J Med Virol, 78(6): 734-40. [Abstract] [Full-text]
131. Toxoplasma gondii, HCV, and HBV seroprevalence and co-infection among HIV-positive and -negative pregnant women in Burkina Faso.
     J Med Virol, 78(6): 730-3. [Abstract] [Full-text]
132. Human immunodeficiency virus type 1 and hepatitis C virus co-infection and viral subtypes at an HIV testing center in Brazil.
     J Med Virol, 78(6): 719-23. [Abstract] [Full-text]
133. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine.
     J Med Virol, 78(6): 787-91. [Abstract] [Full-text]
134. Locally acquired hepatitis E virus infection, El Paso, Texas.
     J Med Virol, 78(6): 741-6. [Abstract] [Full-text]
135. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
     Liver Transpl, 12(5): 762-7. [Abstract] [Full-text]
136. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa.
     Ann Oncol, 17(5): 769-72. [Abstract] [Full-text]
137. Prevalence of hepatitis B among Afghan refugees living in Balochistan, Pakistan.
     Int J Infect Dis, 10(3): 242-7. [Abstract] [Full-text]
138. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10).
     Int J Obes (Lond), 30(5): 794-9. [Abstract] [Full-text]
139. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure.
     Epidemiol Infect, 134(3): 472-7. [Abstract] [Full-text]
140. Clusters of autochthonous hepatitis A cases in a low endemicity area.
     Epidemiol Infect, 134(3): 498-505. [Abstract] [Full-text]
141. Sexual risk for hepatitis B virus infection among hepatitis C virus-negative heroin and cocaine users.
     Epidemiol Infect, 134(3): 478-84. [Abstract] [Full-text]
142. An outbreak of hepatitis A among children and adults in Denmark, August 2002 to February 2003.
     Epidemiol Infect, 134(3): 485-91. [Abstract] [Full-text]
143. The increasing prominence of household transmission of hepatitis A in an area undergoing a shift in endemicity.
     Epidemiol Infect, 134(3): 492-7. [Abstract] [Full-text]
144. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.
     Antimicrob Agents Chemother, 50(5): 1642-8. [Abstract] [Full-text]
145. Variant of hepatitis B virus with primary resistance to adefovir.
     N Engl J Med, 354(17): 1807-12. [Abstract] [Full-text]
146. Immunoglobulin GM and KM allotypes and prevalence of anti-LKM1 autoantibodies in patients with hepatitis C virus infection.
     J Virol, 80(10): 5097-9. [Abstract] [Full-text]
147. The pharmacological potential of Sorbus commixta cortex on blood alcohol concentration and hepatic lipid peroxidation in acute alcohol-treated rats.
     J Pharm Pharmacol, 58(5): 685-93. [Abstract] [Full-text]
148. Aqueous extract of Yin-Chen-Hao decoction, a traditional Chinese prescription, exerts protective effects on concanavalin A-induced hepatitis in mice through inhibition of NF-kappaB.
     J Pharm Pharmacol, 58(5): 677-84. [Abstract] [Full-text]
149. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study.
     Diabetes Care, 29(5): 1096-101. [Abstract] [Full-text]
150. Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection.
     J Eur Acad Dermatol Venereol, 20(4): 442-5. [Abstract] [Full-text]
151. Hepatoprotective sesquiterpene glycosides from Sarcandra glabra.
     J Nat Prod, 69(4): 616-20. [Abstract] [Full-text]

© 2006-2010 Hepatitis Research Today. All Rights Reserved.